- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04838860
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease (SISREMCAD)
A Phase 2 Study of Intrapatient Siltuximab Dose Escalation in Patients With Idiopathic Multicentric Castleman Disease That Has Progressed After Prior Siltuximab Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, two-stage, Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD who progressed with elevated and rising serum C reactive protein (CRP) levels after prior treatment with siltuximab 11 mg/kg every 3 weeks (q3w) without unacceptable toxicity, and is primarily designed to leverage opportunities for intrapatient dose escalation with available clinical, nonclinical, and PK justification as a means to restore or enable disease control.
Enrolling in Stage 1a and Stage 1b of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven iMCD and TAFRO-iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Michigan
-
Lansing, Michigan, United States, 48912
- Edward W. Sparrow Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented history of consensus histologic, laboratory, and clinical diagnostic criteria of iMCD.
- Archival and/or baseline incisional/excisional biopsy for retrospective central histologic confirmation of iMCD.
- CDCNRC-defined disease progression on or after prior treatment with siltuximab at 11 mg/kg q3w without unacceptable toxicity within 12 weeks between the last dose of siltuximab and the date of signed patient informed consent form (ICF).
- At least 1 measurable abnormal lymph node mass that is ≥1 cm in its longest transverse diameter as assessed by computerized tomography (CT) scan that has not been previously irradiated.
- Elevated (>10 mg/L) and rising serum CRP in the absence of additional iMCD treatment.
Evidence of at least an additional one of the following laboratory or clinical signs of iMCD per international, evidence-based consensus diagnostic criteria for HIV or HHV 8-negative iMCD:
- Anemia, thrombocytopenia, hypoalbuminemia, renal dysfunction, or polyclonal hypergammaglobulinemia.
- Constitutional symptoms (night sweats, fever (>38°C), weight loss, or fatigue (CTCAE lymphoma B-symptoms score ≥2), large spleen and/or liver, fluid accumulation, eruptive cherry hemangiomatosis/violaceous papules, or lymphocytic interstitial pneumonitis.
Adequate clinical laboratory measurements within 3 weeks prior to study entry in all parameters below:
- Absolute neutrophil count ≥1.0 × 109/L, hemoglobin <17 g/dL, and platelets ≥50 × 109/L without transfusion, hematopoietic growth factors, or both for >7 days prior to measurement.
- AST, ALT, total bilirubin, and alkaline phosphatase ≤5 × ULN.
- Fasting cholesterol <300 mg/dL and fasting triglyceride <400 mg/dL.
- Age ≥12 years.
Exclusion Criteria:
- Documentation of HIV or HHV-8 infection or presence of other infection-related disorders that resemble clinical or histological features of iMCD
- Diagnosis of any malignant/benign lymphoproliferative disorders
- Diagnosis of autoimmune/autoinflammatory disease
- Treatment with corticosteroids (prednisone dose-equivalent >1 mg/kg/day) within 7 days prior to study entry.
- History of solid organ transplant, allogeneic bone marrow transplant, or allogeneic peripheral blood stem cell transplant.
Previous malignancy with the following exceptions:
- Past malignancy with treatment that was completed at least 2 years before signing informed consent and the patient has no evidence of disease, or
- Concurrent malignancy that is clinically stable and does not require tumor-directed treatment (eg, nonmelanoma skin cancer and carcinoma in situ)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Parallel Arm of iMCD Patients
Enrolling in Stage 1a of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT.
The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
|
Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
Other Names:
|
Active Comparator: Parallel Arm of TAFRO-iMCD Patients
Enrolling in Stage 1b of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven TAFRO-iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT.
The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
|
Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the Clinical Benefit Response (CBR) of Siltuximab
Time Frame: 12 Weeks
|
Assess the clinical benefit response (CBR) of increased siltuximab doses in patients with IL-6-driven (C-reactive protein [CRP]-elevated and rising) idiopathic multicentric Castleman disease (iMCD) after disease progression on the standard siltuximab dose schedule.
CBR defined as complete response (CR), partial response (PR), or stable disease (SD) lasting ≥12 weeks per Castleman Disease Collaborative Network Response Criteria (CDCNRC).
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the safety and tolerability of increased Siltuximab doses
Time Frame: 12 Weeks
|
Incidence of Adverse Events (AEs), serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs), incidence of abnormal laboratory test results incidence of dose-limiting toxicities (DLTs)
|
12 Weeks
|
Pharmacokinetics (Vd)
Time Frame: 12 Weeks
|
To test the patient's drug propensity
|
12 Weeks
|
Pharmacokinetics (CL)
Time Frame: 12 Weeks
|
To test the volume of plasma cleared of drug per unit time
|
12 Weeks
|
Pharmacokinetics (AUC)
Time Frame: 12 Weeks
|
To test the extent of exposure to a drug and its clearance rate from the body
|
12 Weeks
|
Pharmacokinetics (Cmin / Cmax)
Time Frame: 12 Weeks
|
To test the minimum (Cmin) and the maximum (Cmax) blood plasma concentration
|
12 Weeks
|
Pharmacokinetics (Ctrough)
Time Frame: 12 Weeks
|
To test the minimum drug concentration after a dose
|
12 Weeks
|
Pharmacokinetics (Tmax)
Time Frame: 12 Weeks
|
To test the time taken to reach Cmax
|
12 Weeks
|
Evaluate the efficacy of increased siltuximab doses after disease progression on prior siltuximab treatment.
Time Frame: 12 Weeks
|
The primary efficacy endpoint is CBR defined as CR, PR, or SD lasting ≥12 weeks per CDCNRC based on evaluation of biochemical, lymph node, and symptom response
|
12 Weeks
|
Evaluate the immunogenicity of increased siltuximab doses after disease progression on prior siltuximab treatment.
Time Frame: 12 Weeks
|
Immunogenicity will be assessed through the detection of antibodies against siltuximab, and will be conducted via immunoassay ± serum IL-6 levels on Day 1 of Cycle 1, 3, 6 and every 4 cycles thereafter, before administration of siltuximab.
|
12 Weeks
|
To evaluate the patient-reported outcomes (PROs) using the EQ-5D Instrument
Time Frame: 12 Weeks
|
The secondary outcome measures will include the health status measures of the EuroQuality of Life Five Dimensions (EQ-5D) has the following dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension has 3 levels: no problems, some problems, and extreme problems.
The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the 5 dimensions
|
12 Weeks
|
To evaluate the patient-reported outcomes (PROs) using the MCD-SS Instrument
Time Frame: 12 Weeks
|
The Multicentric Castleman disease symptom score (MCD-SS) lists 10 symptoms which are graded on a scale: Did not experience (0); Very mild (2); Mild (4); Moderate (6); Severe (8); Very Severe (10).
The mean score of the ten items is calculated and a higher score indicates more severe symptoms.
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Chris Keuker, MD, Syneos Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EUSA SYL 0002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Multicentric Castleman's Disease
-
EusaPharma (UK) LimitedUniversity of Sheffield (ScHARR); KMC Health Care; Castleman Disease Collaborative...Not yet recruitingIdiopathic Multicentric Castleman's Disease
-
Beijing VDJBio Co., LTD.RecruitingIdiopathic Multicentric Castleman's DiseaseChina
-
Peking Union Medical College HospitalRecruitingZanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial (iMCD)Idiopathic Multicentric Castleman's DiseaseChina
-
Peking Union Medical College HospitalRecruitingIdiopathic Multicentric Castleman's DiseaseChina
-
Hoffmann-La RocheCompleted
-
University of PennsylvaniaRecruitingCastleman Disease | Castleman's Disease, MulticentricUnited States
-
Peking Union Medical College HospitalUnknownMulticentric Castleman DiseaseChina
-
UNC Lineberger Comprehensive Cancer CenterFogarty International Center of the National Institute of HealthRecruitingMulticentric Castleman DiseaseMalawi
-
Janssen Research & Development, LLCCompletedMulticentric Castleman's DiseaseUnited States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Israel, Korea, Republic of, Singapore, Brazil, Belgium, New Zealand, Norway, Egypt, Hong Kong
-
Janssen Research & Development, LLCCompletedMulticentric Castleman's DiseaseUnited States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Belgium, Israel, India, Korea, Republic of, Netherlands, Singapore, Brazil, Russian Federation, New Zealand, Hungary, Norway, Australia, Egypt, Hong Kong, Malaysi...
Clinical Trials on Siltuximab
-
Carla Greenbaum, MDJanssen Research & Development, LLCCompleted
-
Centocor, Inc.CompletedLymphoma, Non-Hodgkin | Multiple Myeloma | Giant Lymph Node HyperplasiaUnited States
-
University of Alabama at BirminghamRecruitingLymphoma, Non-Hodgkin | Multiple Myeloma | Acute Lymphoblastic Leukemia | Cytokine Release Syndrome | ICANSUnited States
-
Janssen Research & Development, LLCCompletedHigh-risk Smoldering Multiple MyelomaUnited States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
-
Janssen Research & Development, LLCCompletedMultiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell NeoplasmUnited States, Belgium, Russian Federation
-
Janssen Research & Development, LLCCompletedMulticentric Castleman's DiseaseUnited States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Israel, Korea, Republic of, Singapore, Brazil, Belgium, New Zealand, Norway, Egypt, Hong Kong
-
Centocor, Inc.Completed
-
H. Lee Moffitt Cancer Center and Research InstituteEUSA Pharma, Inc.RecruitingLarge Granular Lymphocyte LeukemiaUnited States
-
Centocor, Inc.CompletedCarcinoma, Renal CellFrance, United Kingdom, Netherlands, Czech Republic
-
Janssen Research & Development, LLCTerminatedMyelodysplastic SyndromeUnited States, Belgium, Spain, Australia, Sweden, Netherlands, Russian Federation